Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition

BACKGROUND: The PI3K pathway is hyperactivated in many cancers, including 70 % of breast cancers. Pan- and isoform-specific inhibitors of the PI3K pathway are currently being evaluated in clinical trials. However, the clinical responses to PI3K inhibitors when used as single agents are not as effici...

Descripción completa

Detalles Bibliográficos
Autores principales: Leroy, Cedric, Ramos, Pedro, Cornille, Karen, Bonenfant, Debora, Fritsch, Christine, Voshol, Hans, Bentires-Alj, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820873/
https://www.ncbi.nlm.nih.gov/pubmed/27048245
http://dx.doi.org/10.1186/s13058-016-0697-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820873/
https://www.ncbi.nlm.nih.gov/pubmed/27048245
http://dx.doi.org/10.1186/s13058-016-0697-1

Ejemplares similares